Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Moodys
AstraZeneca
Mallinckrodt

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,233,154

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,233,154 protect, and when does it expire?

Patent 10,233,154 protects AKYNZEO and is included in one NDA.

This patent has eight patent family members in eight countries.

Summary for Patent: 10,233,154
Title:Crystalline forms of an NK-1 antagonist
Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
Inventor(s): Bacilieri; Christian (Breganzona, CH), Frasca; Gionata (Minusio, CH)
Assignee: Helsinn Healthcare SA (Pazzallo-Lugano, CH)
Application Number:15/918,868
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,233,154

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,233,154

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015323515   Start Trial
Canada 2960599   Start Trial
China 107001275   Start Trial
European Patent Office 3197871   Start Trial
Japan 2017529380   Start Trial
South Korea 20170063768   Start Trial
Taiwan 201613888   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Boehringer Ingelheim
McKinsey
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.